Berlia Diagnostic & Research Institute Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 14-12-2024
- Paid Up Capital ₹ 1.92 Cr
as on 14-12-2024
- Company Age 21 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.60 M
as on 14-12-2024
- Satisfied Charges ₹ 1.74 Cr
as on 14-12-2024
- Revenue 22.25%
(FY 2017)
- Profit 167.61%
(FY 2017)
- Ebitda 26.47%
(FY 2017)
- Net Worth 4.21%
(FY 2017)
- Total Assets 18.97%
(FY 2017)
About Berlia Diagnostic & Research Institute
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.92 Cr.
The company currently has active open charges totaling ₹3.60 M. The company has closed loans amounting to ₹1.74 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kanta Agarwalla and Ramesh Agarwal serve as directors at the Company.
- CIN/LLPIN
U85120AS2003PTC007199
- Company No.
007199
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Aug 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Dibrugarh, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Berlia Diagnostic & Research Institute?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kanta Agarwalla  | Director | 28-Aug-2003 | Current |
| Ramesh Agarwal | Director | 28-Aug-2003 | Current |
Financial Performance of Berlia Diagnostic & Research Institute.
Berlia Diagnostic & Research Institute Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 22.25% increase. The company also saw a substantial improvement in profitability, with a 167.61% increase in profit. The company's net worth moved up by a moderate rise of 4.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Berlia Diagnostic & Research Institute?
In 2017, Berlia Diagnostic & Research Institute had a promoter holding of 15.56% and a public holding of 84.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Jan 2021 | ₹3.60 M | Open |
Others Creation Date: 21 Nov 2019 | ₹0.40 M | Satisfied |
Others Creation Date: 08 Nov 2019 | ₹0.45 M | Satisfied |
How Many Employees Work at Berlia Diagnostic & Research Institute?
Unlock and access historical data on people associated with Berlia Diagnostic & Research Institute, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Berlia Diagnostic & Research Institute, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Berlia Diagnostic & Research Institute's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
